Performance of the GenoType® MTBDRPlus assay in routine settings: a multicenter study

  • S. Mironova
  • E. Pimkina
  • I. Kontsevaya
  • V. Nikolayevskyy
  • Y. Balabanova
  • G. Skenders
  • T. Kummik
  • F. Drobniewski
Article
First Online:
Received:
Accepted:

Abstract

Former Soviet Union countries including the Baltic States (Latvia, Lithuania, and Estonia) are hot spots for an emerging epidemic of drug resistant tuberculosis (TB). As a part of the development of a co-ordinated network of centers for diagnostic trials across Eastern Europe we conducted a retrospective multicenter analysis of the performance of the GenoType® MTBDRPlus assay for TB identification and susceptibility to isoniazid (INH) and rifampicin (RIF) in routine settings. A total of 1,045 primary samples, 1045 TB cultures derived from these specimens and 306 separate M. tuberculosis isolates tested in 2007–2010 at four participating sites (Tartu, Estonia; Riga, Latvia; Vilnius, Lithuania; and Samara, Russian Federation) were included in the analysis. The pooled sensitivity and specificity values for RIF and INH were 95.3% and 95.5%, 89.9 and 87.1%, respectively; there were no statistically significant variations in performance across sites. The proportion of multidrug resistant (MDR) strains in the collections ranged from 21.8% (in Estonia) to 55.9% (in Russia). In a routine non-trial context, the assay reliably detected both rifampicin and isoniazid resistance. The absence of statistically significant differences between sites suggested that the comparable performance obtained using these assays has helped demonstrate the formation of a successful diagnostic trial network.

Keywords

Drug Susceptibility Testing Pool Sensitivity inhA Gene BACTEC MGIT Direct Specimen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Notes

Acknowledgements

The authors would like to thank all participating sites and laboratory staff for their helpful suggestions and support. This study was funded by EU FP7 grants TB-EURO-GEN (grant No 201483) and TB PAN-NET (grant No 223681).

Conflict of interest statement

The authors declare that they have no conflict of interest.

References

  1. 1.
    Raviglione MC, Smith IM (2007) XDR tuberculosis—implications for global public health. N Engl J Med 356(7):656–659PubMedCrossRefGoogle Scholar
  2. 2.
    Leimane V, Dravniece G, Riekstina V, Sture I, Kammerer S, Chen MP, Skenders G, Holtz TH (2010) Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000–2004. Eur Respir J 36(3):584–593PubMedCrossRefGoogle Scholar
  3. 3.
    Hillemann D, Rusch-Gerdes S, Richter E (2007) Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 45(8):2635–2640PubMedCrossRefGoogle Scholar
  4. 4.
    Huyen MN, Tiemersma EW, Lan NT, Cobelens FG, Dung NH, Sy DN, Buu TN, Kremer K, Hang PT, Caws M, O'Brien R, van Soolingen D (2010) Validation of the GenoType MTBDRplus assay for diagnosis of multidrug resistant tuberculosis in South Vietnam. BMC Infect Dis 10:149PubMedCrossRefGoogle Scholar
  5. 5.
    Migliori GB, Sotgiu G, Lange C, Centis R (2010) Extensively drug-resistant tuberculosis: back to the future. Eur Respir J 36(3):475–477PubMedCrossRefGoogle Scholar
  6. 6.
    WHO (2008) Anti-tuberculosis drug resistance in the world. Fourth global report. WHO/HTM/TB/2008.394. World Health Organization, Geneva, SwitzerlandGoogle Scholar
  7. 7.
    Palomino JC (2005) Nonconventional and new methods in the diagnosis of tuberculosis: feasibility and applicability in the field. Eur Respir J 26(2):339–350PubMedCrossRefGoogle Scholar
  8. 8.
    Hillemann D, Rusch-Gerdes S, Richter E (2009) Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 47(6):1767–1772PubMedCrossRefGoogle Scholar
  9. 9.
    Abebe G, Paasch F, Apers L, Rigouts L, Colebunders R (2010) Tuberculosis drug resistance testing by molecular methods: opportunities and challenges in resource limited settings. J Microbiol Methods 84(2):155–160PubMedCrossRefGoogle Scholar
  10. 10.
    Albert H, Bwanga F, Mukkada S, Nyesiga B, Ademun JP, Lukyamuzi G, Haile M, Hoffner S, Joloba M, O'Brien R (2010) Rapid screening of MDR-TB using molecular line probe assay is feasible in Uganda. BMC Infect Dis 10:41PubMedCrossRefGoogle Scholar
  11. 11.
    Ahmad S, Al-Mutairi NM, Mokaddas E (2009) Comparison of performance of two DNA line probe assays for rapid detection of multidrug-resistant isolates of Mycobacterium tuberculosis. Indian J Exp Biol 47(6):454–462PubMedGoogle Scholar
  12. 12.
    Shah NS, Lan NT, Huyen MN, Laserson K, Iademarco MF, Binkin N, Wells C, Varma JK (2009) Validation of the line-probe assay for rapid detection of rifampicin-resistant Mycobacterium tuberculosis in Vietnam. Int J Tuberc Lung Dis 13(2):247–252PubMedGoogle Scholar
  13. 13.
    WHO (2008) Molecular line probe assays for rapid screening of patients at risk of multidrug resistant tuberculosis (MDR-TB). Policy Statement World Health Organization, Geneva, SwitzerlandGoogle Scholar
  14. 14.
    Evans J, Stead MC, Nicol MP, Segal H (2009) Rapid genotypic assays to identify drug-resistant Mycobacterium tuberculosis in South Africa. J Antimicrob Chemother 63(1):11–16PubMedCrossRefGoogle Scholar
  15. 15.
    Bwanga F, Hoffner S, Haile M, Joloba ML (2009) Direct susceptibility testing for multi drug resistant tuberculosis: a meta-analysis. BMC Infect Dis 9:67PubMedCrossRefGoogle Scholar
  16. 16.
    Barnard M, Albert H, Coetzee G, O'Brien R, Bosman ME (2008) Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med 177(7):787–792PubMedCrossRefGoogle Scholar
  17. 17.
    Bazira J, Asiimwe BB, Joloba ML, Bwanga F, Matee MI (2010) Use of the GenoType(R) MTBDRplus assay to assess drug resistance of Mycobacterium tuberculosis isolates from patients in rural Uganda. BMC Clin Pathol 10:5PubMedCrossRefGoogle Scholar
  18. 18.
    Mokrousov I, Jiao WW, Sun GZ, Liu JW, Valcheva V, Li M, Narvskaya O, Shen AD (2006) Evolution of drug resistance in different sublineages of Mycobacterium tuberculosis Beijing genotype. Antimicrob Agents Chemother 50(8):2820–2823PubMedCrossRefGoogle Scholar
  19. 19.
    Rodrigues C, Shenai S, Sadani M, Sukhadia N, Jani M, Ajbani K, Sodha A, Mehta A (2009) Evaluation of the bactec MGIT 960 TB system for recovery and identification of Mycobacterium tuberculosis complex in a high through put tertiary care centre. Indian J Med Microbiol 27(3):217–221PubMedCrossRefGoogle Scholar
  20. 20.
    Lee JJ, Suo J, Lin CB, Wang JD, Lin TY, Tsai YC (2003) Comparative evaluation of the BACTEC MGIT 960 system with solid medium for isolation of mycobacteria. Int J Tuberc Lung Dis 7(6):569–574PubMedGoogle Scholar
  21. 21.
    WHO (2011) World Health Organization towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015. WHO progress report, 23 March 2011. Report no.: WHO/HTM/TB/2011.3Google Scholar
  22. 22.
    Ling DI, Zwerling AA, Pai M (2008) GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur Respir J 32(5):1165–1174PubMedCrossRefGoogle Scholar
  23. 23.
    Balabanova Y, Drobniewski F, Nikolayevskyy V, Kruuner A, Malomanova N, Simak T, Ilyina N, Zakharova S, Lebedeva N, Alexander HL, O'Brien R, Sohn H, Shakhmistova A, Fedorin I (2009) An integrated approach to rapid diagnosis of tuberculosis and multidrug resistance using liquid culture and molecular methods in Russia. PLoS One 4(9):e7129PubMedCrossRefGoogle Scholar
  24. 24.
    Nikolayevskyy V, Balabanova Y, Simak T, Malomanova N, Fedorin I, Drobniewski F (2009) Performance of the Genotype MTBDRPlus assay in the diagnosis of tuberculosis and drug resistance in Samara Russian Federation. BMC Clin Pathol 9:2PubMedCrossRefGoogle Scholar
  25. 25.
    Miotto P, Saleri N, Dembele M, Ouedraogo M, Badoum G, Pinsi G, Migliori GB, Matteelli A, Cirillo DM (2009) Molecular detection of rifampin and isoniazid resistance to guide chronic TB patient management in Burkina Faso. BMC Infect Dis 9:142PubMedCrossRefGoogle Scholar
  26. 26.
    Anek-Vorapong R, Sinthuwattanawibool C, Podewils LJ, McCarthy K, Ngamlert K, Promsarin B, Varma JK (2010) Validation of the GenoType MTBDRplus assay for detection of MDR-TB in a public health laboratory in Thailand. BMC Infect Dis 10:123PubMedCrossRefGoogle Scholar
  27. 27.
    Skenders G, Fry AM, Prokopovica I, Greckoseja S, Broka L, Metchock B, Holtz TH, Wells CD, Leimane V (2005) Multidrug-resistant tuberculosis detection, Latvia. Emerg Infect Dis 11(9):1461–1463PubMedCrossRefGoogle Scholar
  28. 28.
    Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, Gler MT, Blakemore R, Worodria W, Gray C, Huang L, Caceres T, Mehdiyev R, Raymond L, Whitelaw A, Sagadevan K, Alexander H, Albert H, Cobelens F, Cox H, Alland D, Perkins MD (2011) Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 377(9776):1495–1505PubMedCrossRefGoogle Scholar
  29. 29.
    Ioannidis P, Papaventsis D, Karabela S, Nikolaou S, Panagi M, Raftopoulou E, Konstantinidou E, Marinou I, Kanavaki S (2011) Cepheid GeneXpert MTB/RIF assay for Mycobacterium tuberculosis detection and rifampin resistance identification in patients with substantial clinical indications of tuberculosis and smear-negative microscopy results. J Clin Micobiol 49(8):3068–3070CrossRefGoogle Scholar
  30. 30.
    Rinder H, Mieskes KT, Loscher T (2001) Heteroresistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 5(4):339–345PubMedGoogle Scholar
  31. 31.
    Baldeviano-Vidalon GC, Quispe-Torres N, Bonilla-Asalde C, Gastiaburu-Rodriguez D, Pro-Cuba JE, Llanos-Zavalaga F (2005) Multiple infection with resistant and sensitive M. tuberculosis strains during treatment of pulmonary tuberculosis patients. Int J Tuberc Lung Dis 9(10):1155–1160PubMedGoogle Scholar
  32. 32.
    Hofmann-Thiel S, van Ingen J, Feldmann K, Turaev L, Uzakova GT, Murmusaeva G, van Soolingen D, Hoffmann H (2009) Mechanisms of heteroresistance to isoniazid and rifampin of Mycobacterium tuberculosis in Tashkent, Uzbekistan. Eur Respir J 33(2):368–374PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • S. Mironova
    • 1
  • E. Pimkina
    • 2
  • I. Kontsevaya
    • 1
  • V. Nikolayevskyy
    • 3
  • Y. Balabanova
    • 3
  • G. Skenders
    • 4
  • T. Kummik
    • 5
  • F. Drobniewski
    • 3
  1. 1.Samara Oblast TB ServiceSamaraRussian Federation
  2. 2.National Tuberculosis and Infectious Diseases University HospitalVilniusLithuania
  3. 3.UK Health Protection Agency National Mycobacterium Reference Laboratory, Clinical TB and HIV Research Group, Institute for Cell and Molecular Science, Barts and the London School of MedicineQueen Mary College University of LondonLondonUK
  4. 4.State Agency “Infectology Center of Latvia”, Clinic for Tuberculosis and Lung DiseasesMycobacteriology Department, “Upeslejas” StopinunovadsRigaLatvia
  5. 5.United Laboratory, Department of MycobacteriologyTartu University HospitalTartuEstonia

Personalised recommendations